Injectable testosterone is associated with a higher short-term risk of cardiovascular events compared with testosterone gel or patch formulations, according to a new epidemiologic study of three large ...

The Food and Drug Administration (FDA) has, for the third time, declined approval of the long-acting testosterone undecanoate injection product (Aveed, Endo Pharma Solutions) for the treatment of men ...

Intramuscular injection of testerosterone replacement therapy confers greater health benefits and lower cardiovascular risks than transdermal administration by skin patch or gel, a new study concludes ...

Drugmaker Endo Pharmaceuticals announced Thursday that it received U.S. approval for its long-acting testosterone injection Aveed, which joins a crowded field of hormone-boosting drugs aimed at aging ...